UNLABELLED: We have developed a practice procedure for prostate lymphoscintigraphy using SPECT/CT and filtered (99m)Tc-sulfur nanocolloid, as an alternative to the proprietary product (99m)Tc-Nanocoll, which is not approved in the United States. METHODS: Ten patients were enrolled for this study, and all received radiotracer prepared using a 100-nm membrane filter at a commercial radiopharmacy. Whole-body scans and SPECT/CT studies were performed within 1.5-3 h after the radiotracer had been administered directly into 6 locations of the prostate gland under transrectal ultrasound guidance. The radiation dose was estimated from the first 3 patients. Lymphatic drainage mapping was performed, and lymph nodes were identified. RESULTS: The estimated radiation dose ranged from 3.9 to 5.2 mSv/MBq. The locations of lymph nodes draining the prostate gland were similar to those found using the proprietary product. CONCLUSION: When the proprietary radiolabeled nanocolloid indicated for lymphoscintigraphy is not available, prostate lymph node mapping and identification are still feasible using filtered (99m)Tc-sulfur nanocolloid.
UNLABELLED: We have developed a practice procedure for prostate lymphoscintigraphy using SPECT/CT and filtered (99m)Tc-sulfur nanocolloid, as an alternative to the proprietary product (99m)Tc-Nanocoll, which is not approved in the United States. METHODS: Ten patients were enrolled for this study, and all received radiotracer prepared using a 100-nm membrane filter at a commercial radiopharmacy. Whole-body scans and SPECT/CT studies were performed within 1.5-3 h after the radiotracer had been administered directly into 6 locations of the prostate gland under transrectal ultrasound guidance. The radiation dose was estimated from the first 3 patients. Lymphatic drainage mapping was performed, and lymph nodes were identified. RESULTS: The estimated radiation dose ranged from 3.9 to 5.2 mSv/MBq. The locations of lymph nodes draining the prostate gland were similar to those found using the proprietary product. CONCLUSION: When the proprietary radiolabeled nanocolloid indicated for lymphoscintigraphy is not available, prostate lymph node mapping and identification are still feasible using filtered (99m)Tc-sulfur nanocolloid.
Authors: Mack Roach; Michelle DeSilvio; Richard Valicenti; David Grignon; Sucha O Asbell; Colleen Lawton; Charles R Thomas; William U Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-01 Impact factor: 7.038
Authors: Lenka Vermeeren; Sara H Muller; Willem Meinhardt; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-20 Impact factor: 9.236
Authors: Ute Ganswindt; Frank Paulsen; Stefan Corvin; Kai Eichhorn; Stefan Glocker; Ilse Hundt; Mattias Birkner; Markus Alber; Aristotelis Anastasiadis; Arnulf Stenzl; Roland Bares; Wilfried Budach; Michael Bamberg; Claus Belka Journal: BMC Cancer Date: 2005-07-28 Impact factor: 4.430
Authors: Daniel L J Thorek; David Ulmert; Ndeye-Fatou M Diop; Mihaela E Lupu; Michael G Doran; Ruimin Huang; Diane S Abou; Steven M Larson; Jan Grimm Journal: Nat Commun Date: 2014 Impact factor: 14.919
Authors: Shentian Wu; Edward Helal-Neto; Ana Paula Dos Santos Matos; Amir Jafari; Ján Kozempel; Yuri José de Albuquerque Silva; Carolina Serrano-Larrea; Severino Alves Junior; Eduardo Ricci-Junior; Frank Alexis; Ralph Santos-Oliveira Journal: Drug Deliv Date: 2020-12 Impact factor: 6.419